BPMC Blueprint Medicines Corp

$129.46

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 11/17/2025

About Blueprint Medicines Corp

Blueprint Medicines Corporation, a precision therapy company, develops drugs for people with cancer and blood disorders, and multiple programs for genomically defined cancers, systemic mastocytosis, and cancer immunotherapy in the United States and Europe. The company is headquartered in Cambridge, Massachusetts.

Website: https://www.blueprintmedicines.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1597264
Address
45 SIDNEY STREET, CAMBRIDGE, MA, US
Valuation
Market Cap
$5.41B
P/E Ratio
nan
PEG Ratio
0.00
Price to Book
18.12
Performance
EPS
$-1.07
Dividend Yield
—
Profit Margin
-13.20%
ROE
-31.30%
Technicals
50D MA
$90.21
200D MA
$95.21
52W High
$121.90
52W Low
$73.04
Fundamentals
Shares Outstanding
64M
Target Price
$124.90
Beta
0.75

BPMC EPS Estimates vs Actual

● Estimated
● Actual

BPMC News & Sentiment

Nov 17, 2025 • Zacks Commentary SOMEWHAT-BULLISH
MRK to Buy Cidara for $9.2B: Focus on Buyout Spree Heading Into 2026
Merck's $9.2 billion proposed Cidara acquisition will add CD388 to the pipeline, boosting the respiratory portfolio and fueling its ongoing strategic M&A momentum.
Oct 30, 2025 • GlobeNewswire SOMEWHAT-BULLISH
DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors
Châtillon, France, October ...
Oct 24, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Sanofi Q3 Earnings Beat, Dupixent Drives Growth as Vaccines Decline
Sanofi's Q3 earnings top forecasts as Dupixent surges past EUR 4B in sales, offsetting weakness in vaccines.
Sep 29, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Can RIGL's Oncology Portfolio Create Long-Term Value Beyond Tavalisse?
Rigel's Tavalisse drives strong sales, but expansion with Rezlidhia, Gavreto, and pipeline candidates could shape its long-term growth story.
Sep 25, 2025 • Zacks Commentary SOMEWHAT-BULLISH
RIGL vs. FOLD: Which Biotech Stock Offers Better Growth Potential?
Rigel and Amicus are advancing rare disease therapies, with rising sales from key drugs fueling growth prospects in 2025.
Sep 24, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Zacks Industry Outlook Highlights Halozyme Therapeutics, Akero Therapeutics, Kiniska Pharmaceuticals, ANI Pharmaceuticals and Twist BioScience
Biotech stocks gain momentum as M&A, AI-driven drug discovery, and new approvals fuel growth. Halozyme, Akero, Kiniska, ANI and Twist stand out.
Sentiment Snapshot

Average Sentiment Score:

0.183
50 articles with scored sentiment

Overall Sentiment:

Bullish

BPMC Reported Earnings

Apr 30, 2025
Mar 31, 2025 (Pre market)
0.0 Surprise
  • Reported EPS: $0.00
  • Estimate: $-1.66
  • Whisper: —
  • Surprise %: 0.0%
Feb 13, 2025
Dec 31, 2024 (Pre market)
-0.08 Surprise
  • Reported EPS: $-0.79
  • Estimate: $-0.71
  • Whisper: —
  • Surprise %: -10.6%
Oct 30, 2024
Sep 30, 2024 (Pre market)
0.08 Surprise
  • Reported EPS: $-0.89
  • Estimate: $-0.97
  • Whisper: —
  • Surprise %: 8.2%
Aug 01, 2024
Jun 30, 2024 (Pre market)
0.49 Surprise
  • Reported EPS: $-0.80
  • Estimate: $-1.29
  • Whisper: —
  • Surprise %: 38.0%
May 02, 2024
Mar 31, 2024 (Pre market)
3.06 Surprise
  • Reported EPS: $1.40
  • Estimate: $-1.66
  • Whisper: —
  • Surprise %: 184.3%
Feb 15, 2024
Dec 31, 2023 (Pre market)
0.22 Surprise
  • Reported EPS: $-1.82
  • Estimate: $-2.04
  • Whisper: —
  • Surprise %: 10.8%
Oct 26, 2023
Sep 30, 2023 (Pre market)
0.17 Surprise
  • Reported EPS: $-2.20
  • Estimate: $-2.37
  • Whisper: —
  • Surprise %: 7.2%
Aug 02, 2023
Jun 30, 2023 (Pre market)
0.35 Surprise
  • Reported EPS: $-2.19
  • Estimate: $-2.54
  • Whisper: —
  • Surprise %: 13.8%
May 04, 2023
Mar 31, 2023 (Pre market)
0.52 Surprise
  • Reported EPS: $-2.15
  • Estimate: $-2.67
  • Whisper: —
  • Surprise %: 19.5%

Financials